Dissecting "PI3Kness": The complexity of personalized therapy for ovarian cancer

Cancer Discovery

Volumn 2, Issue 1, 2012, Pages 16-18

  Bast, Robert C ^a   Mills, Gordon B ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; ENZASTAURIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEFITINIB; IMATINIB; ISOPROTEIN; K RAS PROTEIN; LAPATINIB; MIFEPRISTONE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3, 4, 5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHATIDYLINOSITOL 4, 5 BISPHOSPHATE 3 KINASE; PLATINUM; PROTEIN KINASE B BETA; PROTEIN KINASE B INHIBITOR; PROTEIN P53; RETINOBLASTOMA PROTEIN; SOMATOMEDIN RECEPTOR; SORAFENIB; TEMSIROLIMUS; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR NFAT; UNCLASSIFIED DRUG; VORINOSTAT;

ARTICLE; CANCER GROWTH; CANCER STAGING; DNA REPAIR; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC DRIFT; GENOTYPE; HUMAN; MUTATIONAL ANALYSIS; ONCOGENE RAS; OVARY CANCER; PERSONALIZED MEDICINE; SIGNAL TRANSDUCTION;

EID: 84859416701     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-11-0323     Document Type: Article

References (13)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics 2009. CA Cancer J Clin 2009;9:225-49.
2. Bookman M, Brady MF, McGuire WP, Harper PG, Alberts DS, Friedlander M, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a phase III trial of the Gynecologic Cancer Intergroup J Clin Oncol 2009;27:1419-25.
3. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer 2009;9:415-28.
4. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
5. Cheng JQ, Godwin AK, Bellacosa A, Taguchi T, Franke TF, Hamilton TC, et al. AKT2, a putative oncogene encoding a member of a subfamily of protein-serine/threonine kinases, is amplified in human ovarian carcinomas. Proc Natl Acad Sci U S A 1992;89:9267-71.
6. Shayesteh L, Lu Y, Kuo WL, Baldocchi R, Godfrey T, Collins C, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999;21:99-102.
7. Hu L, Zaloudek C, Mills GB, Gray J, Jaffe RB. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res 2000;6:880-6.
8. Hers I, Vincent EE, Tavare JM. Akt signaling in health and disease. Cellular Signalling 2011;23:1515-27.
9. I. Mende S, Malstrom PN, Tsichlis PN, Vogt PK, Aoki M. Oncogenic transformation induced by membrane targeted Akt2 and Akt3. Oncogene 2001;20:4419-23.
10. Hanrahan AJ, Schultz N, Westfal ML, Sakr RA, Giri DD, Scarperi S, et al. Genomic complexity and AKT dependence in serous ovarian cancer. Cancer Discovery 2012;2;56-67.
11. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6.
12. Usui I, Haruta T, Iwata M, Takano A, Uno T, Kawahara J, et al. Retinoblastoma protein phosphorylation via PI 3-kinase and mTOR pathway regulates adipocyte differentiation. Biochem Biophys Res Commun 2000;275:115-20.
13. Tsimberadou AM, Iskander NG, Hong DS, Wheler JJ, Fu S, Piha-Paul SA, et al. Personalized medicine in a phase I clinical trials program: The M.D. Anderson Cancer Center initiative. J Clin Oncol 2011;29:abstract CRA2500.